Stock BIOCQ BIOCEPT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Biocept, Inc.

Equities

BIOCQ

US09072V6002

Delayed OTC Markets
Other stock markets
 20:02:01 23/04/2024 BST 		5-day change 1st Jan Change
0.0001 USD 0.00% Intraday chart for Biocept, Inc. 0.00% -99.76%
04-26 Motion for Asset Sale Approved for Biocept, Inc. CI
04-02 Motion for Asset Sale Approved for Biocept, Inc. CI

Evolution of the average Target Price on Biocept, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d08a1f869b13c4.bc_4mSI5jgzCxxXeZOIrE48mwCEbU9dSXm1kb6FDx9g.J6yg8VphwUuA9X_tM5p5cOYT80s2IrgEAV0tHNYB_ocAio7-Tg7PPqT0LQ~28de959bcf1a6586a660ceca3b73526e

Analyst Recommendations on Biocept, Inc.

Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike MT
Maxim Group Downgrades Biocept to Hold From Buy MT
Maxim Group Adjusts Biocept Price Target to $4 From $5, Maintains Buy Rating MT
Maxim Group Adjusts Biocept Price Target to $7 From $12, Maintains Buy Rating MT
BIOCEPT : Brookline Capital Assumes Coverage on Biocept With Buy Rating, $14 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0001
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Biocept, Inc.

Maxim
Brookline Capital Management

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BIOCQ Stock
  4. Consensus Biocept, Inc.